AlphAIAlphAI — Financial news for AI agents
newsable.asianetnews.comAUG 282 min read$ALNY

IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY

Ionis (IONS) and AstraZeneca (AZN) presented full data from a failed trial of Wainua for transthyretin amyloid cardiomyopathy (ATTR-CM). Jefferies sees neutral to negative implications for Alnylam (ALNY), which is developing similar drugs. ALNY shares closed flat, IONS down 2%, and AZN down 1% on Friday. The trial missed its primary goal, raising doubts about ALNY's TTR business.

Original reporting
newsable.asianetnews.com
Published Aug 28, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 29, 2026, 12:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY — source image
Source · newsable.asianetnews.com
Decision brief

The 30-second read

$ALNYBearishHigh
01

Why it matters

The neutral to negative read‑through suggests silencing may not add value over stabilizers, affecting pipeline valuations.

02

Market read

First full data release from a pivotal ATTR‑CM trial, causing immediate price moves in three biotech stocks.

03

What to watch

Potential for future combination therapies and the existing approved indication for nerve damage could sustain revenue.

Relevance 8/10Novelty 9/10Timing: Friday after‑hours release of full trial data

Background

The CARDIO‑TTRansform trial was the largest ATTR‑CM study to date, testing eplontersen (Wainua) versus placebo.

Company-level read

Ticker impact

$ALNYBearishHigh confidence
Context

Alnylam shares fell up to 5% after full data from the failed cardiomyopathy trial involving Ionis and AstraZeneca were released.

Expected impact

downward pressure on ALNY price in the short term

Evidence & confidence

The trial missed its primary endpoint and analysts view the result as a setback for Alnylam's pipeline.

$IONSBearishHigh confidence
Context

Ionis closed down 2% after the full results of its co‑developed eplontersen (Wainua) trial were disclosed.

Expected impact

moderate downside for IONS

Evidence & confidence

Trial data was largely as expected but failed to show statistical significance, dampening outlook.

$AZNBearishHigh confidence
Context

AstraZeneca's U.S. shares slipped about 1% after the trial data were presented.

Expected impact

slight short‑term pressure on AZN

Evidence & confidence

Even though the impact is smaller, the trial outcome reflects on the co‑development partner.

Market effects

Sector

TTR biotech sector faces heightened scrutiny; other silencing approaches may be re‑evaluated.

Regional

US biotech stocks could see modest pullback following the news.

Global

Limited to companies with TTR programs; broader market impact minimal.

Counterpoint

What could challenge this read

The data were largely as expected; investors may view the dip as a buying opportunity if long‑term pipeline remains strong.

Key entities

  • Company
    Alnylam Pharmaceuticals

    Biotech developing TTR silencing therapies.

  • Company
    Ionis Pharmaceuticals

    Co‑developer of eplontersen.

  • Company
    AstraZeneca

    Partner in eplontersen development.

Read at source← All news

Related articles

SEP 20
$IONSMedAI 8/10

Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook

Ionis Pharmaceuticals (IONS) shares have fallen over 40% this year, despite analysts maintaining an average price target of $83.82. The company has six approved therapies, primarily for rare diseases, and is developing eight more in late-stage trials. Ionis reported a 40.7% revenue decline and a net loss in Q2, but analysts highlight its antisense oligonucleotide technology and potential for future growth.

aol.com2 min
SEP 19
$AZNMedAI 8/10

AstraZeneca TAGRISSO cuts death risk 47% in early

AstraZeneca (AZN) reported that TAGRISSO reduced death risk by 47% in early-stage lung cancer patients over eight years, per ADAURA trial data. The drug showed 74% survival vs. 58% for placebo in primary population. AZN shares rose 1.86% premarket. Additionally, AZN's tozorakimab cut COPD exacerbations by 29-34% in Phase III trials, with FDA Priority Review expected Q1 2027.

scanx.trade2 min
SEP 19
$IONSMedAI 8/10

Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks

Ionis Pharmaceuticals is focusing on growing TRYNGOLZA, a treatment for severe hypertriglyceridemia, while facing setbacks in its cardiovascular pipeline. The company is expanding TRYNGOLZA's market through disease awareness and physician education. Ionis is also advancing ION775, a follow-on candidate for sHTG, with phase II trials underway. However, the CARDIO-TTRansform study of eplontersen did not meet its primary endpoint, and the pelacarsen trial in Lp(a) cardiomyopathy was disappointing.

finance.yahoo.com2 min
SEP 19
$IONSHighAI 9/10

First drug to treat Alexander disease wins FDA approval

The FDA approved Zanvastro, the first drug to treat Alexander disease, a rare neurological disorder. Developed by Ionis Pharmaceuticals, it targets the GFAP protein. Clinical trials showed motor function stabilization and improvement. The drug will be available in the U.S. soon, with global distribution via Recordati.

madison.com2 min
SEP 19
$IONSHighAI 8/10

Pelacarsen Trial Failure Might Change The Case For Investing In Ionis Stock (IONS)

Novartis and Ionis Pharmaceuticals' pelacarsen failed to reduce cardiovascular events in a Phase 3 trial, despite lowering lipoprotein(a) levels. This setback removes a potential revenue stream for Ionis, increasing pressure on its other late-stage RNA medicines. Analysts project $2.3B revenue and $222.2M earnings for Ionis by 2029, but the outcome raises execution risks and may extend the company's loss-making period.

simplywall.st2 min